The stock rose 7.3% to $133.02 in recent trading, providing a much-needed lift for a ticker that has declined roughly 7% over the past year. Investors focused on the top-line strength, as total sales grew 14% to reach $962.7 million during the fourth quarter. This performance helped offset a decline in adjusted earnings per share, which fell to $1.25 from $1.62 in the same period last year.

Specialized Demand Fuels Revenue

The company’s prescription division benefited from a surge in demand for systemic nasal drug delivery, particularly for therapies targeting the central nervous system and pain management. Furthermore, the injectables division saw gains tied to the rapid expansion of the GLP-1 market, where AptarGroup provides critical elastomeric components.

Management noted that recent performance faced difficult comparisons due to a previous one-time ramp-up in naloxone production. For the first quarter of the new fiscal year, the company expects adjusted earnings to land between $1.13 and $1.21 per share, according to the official report.